Meacor

Executive Summary

Meacor is a private medical device company developing minimally invasive transcatheter solutions for heart valve repair, focusing initially on mitral and tricuspid valve regurgitation. Its lead investigational device, CryoCinch, is a novel catheter system designed to replicate the surgical standard of care without requiring open-heart surgery. Founded in 2018 and headquartered in Cambridge, MA, the company aims to address the large unmet need for less invasive treatment options in structural heart disease. While Meacor operates in a competitive landscape with established players (e.g., Abbott, Edwards Lifesciences), its unique cryo-based approach could differentiate it by potentially offering more durable and reproducible results. The company is still in early stages, with no disclosed funding or partnership events, and no publicly available clinical data. However, the strong clinical need and innovative technology provide a solid foundation for future growth, contingent on successful technical development and clinical validation.

Upcoming Catalysts (preview)

• Q1 2027First-in-human clinical trial initiation for CryoCinch60% success
• Q3 2026FDA IDE approval for CryoCinch50% success
• Q4 2026Series A or B financing round70% success